Search Results

Serina Therapeutics, Inc., a clinical-stage biotechnology company focused on developing its proprietary POZ PlatformTM drug delivery technology announced the appointment of Dr. Simba Gill as Executive Chairman.

Enable Injections, Inc. and Serina Therapeutics announced a partnership to develop and commercialize SER-252 in combination with enFuse for the treatment of Parkinson’s disease.

Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, today announced the closing of its previously announced merger with a wholly-owned subsidiary of AgeX Therapeutics, Inc.

Serina Therapeutics, a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, reported financial results for the quarter ended March 31, 2024 and provided business highlights.

Serina Therapeutics, Inc. today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.

Serina Therapeutics, Inc., a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction.